These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32615576)

  • 21. [Effects of parathyroid hormone gene polymorphism on cardiovascular mortality].
    Tsujimoto Y; Tabata T; Inoue T; Tahara H; Shoji T; Shinohara K; Inaba M; Nishizawa Y
    Clin Calcium; 2005 Sep; 15 Suppl 1():106-9; discussion 109. PubMed ID: 16272640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Control Study on Hemoperfusion Combined with Hemodialysis versus Standard Hemodialysis: Effects on Middle-Molecular-Weight Toxins and Uremic Pruritus.
    Zhao D; Wang Y; Wang Y; Jiang A; Cao N; He Y; Wang J; Guo Z; Liu W; Shi W; Hao L; Li J; Li W; Wang C; Wang J; Lin H; Shi W; Wang L; Jiang H; Ding G; Li Y; Hu W; Yue H; Liu J; Yang X; Yang Y; Liu G; Li H; Xiao Y; Wang N; Jiang G; Ma G; Wang J; Li Y; Li R; Li Q; Sun S; Jiao J; Xi C; Cai G; Sun X; Chen X
    Blood Purif; 2022 Aug; ():1-11. PubMed ID: 35952629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional hemoperfusion is associated with improved overall survival and self-reported sleep disturbance in patients on hemodialysis.
    Gu YH; Yang XH; Pan LH; Zhan XL; Guo LL; Jin HM
    Int J Artif Organs; 2019 Jul; 42(7):347-353. PubMed ID: 30917741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients.
    Bolignano D; Greco M; Arcidiacono V; Tripolino O; Vita C; Provenzano M; Donato C; Chiarella S; Fuiano G; De Sarro G; Russo E; Andreucci M; Foti DP; Coppolino G
    Int Urol Nephrol; 2021 Jan; 53(1):171-175. PubMed ID: 32794117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
    Li J; Li D; Xu Y; Wang A; Xu C; Yu C
    Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart Rate Variability Change Before and After Hemodialysis is Associated with Overall and Cardiovascular Mortality in Hemodialysis.
    Chen SC; Huang JC; Tsai YC; Hsiu-Chin Mai RN; Jui-Hsin Chen RN; Kuo PL; Chang JM; Hwang SJ; Chen HC
    Sci Rep; 2016 Feb; 6():20597. PubMed ID: 26854202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemoperfusion as an Adjuvant Therapy in Maintenance Hemodialysis Patients with Severe COVID-19: A Single Centre Experience.
    Wardoyo EY; Sari AP; Djojo AY; Sarwono J; Mokoagow MI; Darnindro N; Nasarudin J; Epriliawati M; Manurung A; Iskandar M; Wibisana KA; Widyastuti AAA; Mardiyah R
    Acta Med Indones; 2022 Jul; 54(3):444-450. PubMed ID: 36156468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia.
    Avram MM; Sreedhara R; Avram DK; Muchnick RA; Fein P
    Am J Kidney Dis; 1996 Dec; 28(6):924-30. PubMed ID: 8957048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
    Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
    Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.
    ; Shoji T; Inaba M; Fukagawa M; Ando R; Emoto M; Fujii H; Fujimori A; Fukui M; Hase H; Hashimoto T; Hirakata H; Honda H; Hosoya T; Ikari Y; Inaguma D; Inoue T; Isaka Y; Iseki K; Ishimura E; Itami N; Ito C; Kakuta T; Kawai T; Kawanishi H; Kobayashi S; Kumagai J; Maekawa K; Masakane I; Minakuchi J; Mitsuiki K; Mizuguchi T; Morimoto S; Murohara T; Nakatani T; Negi S; Nishi S; Nishikawa M; Ogawa T; Ohta K; Ohtake T; Okamura M; Okuno S; Shigematsu T; Sugimoto T; Suzuki M; Tahara H; Takemoto Y; Tanaka K; Tominaga Y; Tsubakihara Y; Tsujimoto Y; Tsuruya K; Ueda S; Watanabe Y; Yamagata K; Yamakawa T; Yano S; Yokoyama K; Yorioka N; Yoshiyama M; Nishizawa Y
    JAMA; 2018 Dec; 320(22):2325-2334. PubMed ID: 30535217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.
    Merle E; Roth H; London GM; Jean G; Hannedouche T; Bouchet JL; Drüeke T; Fouque D; Daugas E;
    Kidney Int; 2016 Mar; 89(3):666-74. PubMed ID: 26880460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relationships between hyperparathyroidism and Helicobacter pylori infection in long-term hemodialysis patients].
    Bednarek-Skublewska A; Schabowski J; Majdan M; Baranowicz-Gaszczyk I; Ksiazek A
    Pol Arch Med Wewn; 2001 Mar; 105(3):191-6. PubMed ID: 11680262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography.
    Pilz S; Tomaschitz A; Drechsler C; Ritz E; Boehm BO; Grammer TB; März W
    Eur Heart J; 2010 Jul; 31(13):1591-8. PubMed ID: 20439261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the in vitro efficacy of hemodialysis, hemoperfusion, and the combined approach on the removal of metaldehyde from canine plasma.
    Mauser EL; Puschner B; Reese S; Hartmann K; Doerfelt R
    J Vet Emerg Crit Care (San Antonio); 2016 Jul; 26(4):516-23. PubMed ID: 27219514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism.
    Iwamoto N; Sato N; Nishida M; Hashimoto T; Kobayashi H; Yamasaki S; Ono T; Nishimura M; Tokoro T; Sakoda C; Murakawa M; Okino K; Okamoto Y; Imai R; Adachi N; Ninomiya K; Mabuchi H; Koyama M; Nakanouchi T; Iseki K
    J Nephrol; 2012; 25(5):755-63. PubMed ID: 22135031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent Hemoperfusion and Hemodialysis in Patients with Acute Pesticide Intoxication.
    Park S; Lee S; Park S; Gil H; Lee E; Yang J; Hong S
    Blood Purif; 2016; 42(4):329-336. PubMed ID: 27771705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients.
    Zitt E; Kirsch AH; Haueis M; Strasak A; Neyer U; Mayer G; Rosenkranz AR
    Clin Nephrol; 2011 Apr; 75(4):309-18. PubMed ID: 21426885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low serum uric acid levels increase the risk of all-cause death and cardiovascular death in hemodialysis patients.
    Li M; Ye ZC; Li CM; Zhao WB; Tang H; Liu X; Peng H; Lou TQ
    Ren Fail; 2020 Nov; 42(1):315-322. PubMed ID: 32223483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose metabolism, lipidic pattern, apolipoprotein A and B during hemodialysis with cuprophan and hemodialysis-hemoperfusion.
    Allegra V; Mengozzi G; Vasile A
    Int J Artif Organs; 1989 Jan; 12(1):31-5. PubMed ID: 2925258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.